These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3815730)

  • 1. Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
    Markman M; Chan TC; Cleary S; Howell SB
    Cancer Chemother Pharmacol; 1987; 19(1):80-3. PubMed ID: 3815730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
    Chan TC; Markman M; Cleary S; Howell SB
    Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
    Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
    Casper ES; Vale K; Williams LJ; Martin DS; Young CW
    Cancer Res; 1983 May; 43(5):2324-9. PubMed ID: 6831457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
    Chan TC; Howell SB
    Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma.
    Casper ES; Baselga J; Smart TB; Magill GB; Markman M; Ranhosky A
    Cancer Chemother Pharmacol; 1991; 28(1):51-4. PubMed ID: 2040033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
    Erlichman C; Vidgen D
    Biochem Pharmacol; 1984 Oct; 33(20):3177-81. PubMed ID: 6487365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
    J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
    Creagan ET; O'Connell MJ; Kovach JS
    Cancer; 1983 Aug; 52(4):615-8. PubMed ID: 6861099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Ardalan B; Ucar A; Reddy R; Livingstone AS; Markoe A; Schwade J; Richman SP; Donofrio K
    Cancer; 1994 Oct; 74(7):1869-73. PubMed ID: 8082092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-(phosphonacetyl)-L-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group.
    Bramwell V; Van Oosterom A; Mouridsen HT; Cheix F; Somers R; Thomas D; Rozencweig M
    Eur J Cancer Clin Oncol; 1982 Jan; 18(1):81-4. PubMed ID: 6211362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of combination therapy with PALA and 5-FU.
    Meshad MW; Ervin TJ; Kufe D; Johnson RK; Blum RH; Frei E
    Cancer Treat Rep; 1981; 65(3-4):331-4. PubMed ID: 6263472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Valdivieso M; Moore EC; Burgess AM; Marti JR; Russ J; Plunkett W; Loo TL; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1980; 64(2-3):285-92. PubMed ID: 7407763
    [No Abstract]   [Full Text] [Related]  

  • 14. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
    Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
    Jodrell DI; Oster W; Kerr DJ; Canney PA; Yosef H; Steward WP; Kaye SB; Cassidy J
    Eur J Cancer; 1994; 30A(7):950-5. PubMed ID: 7946590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
    Hageboutros A; Rogatko A; Newman EM; McAleer C; Brennan J; LaCreta FP; Hudes GR; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1995; 35(3):205-12. PubMed ID: 7805178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B; Sridhar KS; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Fodor M; Livingstone A
    Cancer; 1991 Sep; 68(6):1242-6. PubMed ID: 1873776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group.
    Paridaens R; Mouridsen HT; Palshof T; Cocconi G; Van Oosterom A; Rotmensz N; Sylvester R; Heuson JC; Rozencweig M
    Eur J Cancer Clin Oncol; 1982 Jan; 18(1):67-70. PubMed ID: 6211361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
    Rosvold E; Schilder R; Walczak J; DiFino SM; Flynn PJ; Banerjee TK; Heim WJ; Engstrom PF; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1992; 29(4):305-8. PubMed ID: 1537077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
    Weiss GR; Ervin TJ; Meshad MW; Schade D; Branfman AR; Bruni RJ; Chadwick M; Kufe DW
    Cancer Chemother Pharmacol; 1982; 8(3):301-4. PubMed ID: 7127661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.